Bank of America
PRLD icon

Bank of America’s Prelude Therapeutics PRLD Stock Holding History

Bank of America’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$193K Buy
56,525
+46,717
+476% +$122K ﹤0.01% 5373
2025
Q4 		$28.4K Buy
9,808
+960
+11% +$1.62K ﹤0.01% 5977
2025
Q3 		$12.7K Sell
8,848
-2,445
-22% -$2.45K ﹤0.01% 7157
2025
Q2 		$9.14K Sell
11,293
-4,153
-27% -$3.6K ﹤0.01% 7212
2025
Q1 		$11.9K Sell
15,446
-5,208
-25% -$4.86K ﹤0.01% 7088
2024
Q4 		$26.3K Sell
20,654
-4,290
-17% -$5.69K ﹤0.01% 6785
2024
Q3 		$51.6K Sell
24,944
-9,334
-27% -$43.2K ﹤0.01% 6529
2024
Q2 		$131K Buy
34,278
+2,014
+6% +$8.2K ﹤0.01% 6122
2024
Q1 		$153K Sell
32,264
-5,226
-14% -$20.3K ﹤0.01% 6022
2023
Q4 		$160K Sell
37,490
-15,157
-29% -$46.1K ﹤0.01% 6193
2023
Q3 		$163K Buy
52,647
+41,157
+358% +$154K ﹤0.01% 6007
2023
Q2 		$51.7K Sell
11,490
-16,696
-59% -$99.8K ﹤0.01% 6454
2023
Q1 		$161K Sell
28,186
-129,638
-82% -$791K ﹤0.01% 6033
2022
Q4 		$953K Sell
157,824
-9,654
-6% -$61.9K ﹤0.01% 4889
2022
Q3 		$1.11M Buy
167,478
+33,983
+25% +$229K ﹤0.01% 4814
2022
Q2 		$697K Sell
133,495
-1,742
-1% -$8.87K ﹤0.01% 5200
2022
Q1 		$933K Buy
135,237
+56,755
+72% +$519K ﹤0.01% 5342
2021
Q4 		$977K Buy
78,482
+71,387
+1,006% +$1.16M ﹤0.01% 5304
2021
Q3 		$222K Buy
7,095
+2,073
+41% +$67.1K ﹤0.01% 6229
2021
Q2 		$145K Sell
5,022
-11,399
-69% -$406K ﹤0.01% 6296
2021
Q1 		$711K Buy
16,421
+15,931
+3,251% +$1.06M ﹤0.01% 5102
2020
Q4 		$35K Buy
490
+480
+4,800% +$23.9K ﹤0.01% 6449
2020
Q3 		$0 Buy
+10
New +$282 ﹤0.01% 7117

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America's PRLD Position: Q1 2026 in Review

Bank of America increased its Prelude Therapeutics (PRLD) stake by 476% in Q1 2026, buying an estimated $122K and bringing the position to 56,525 shares worth $193K. The position accounts for ﹤0.01% of the portfolio, ranked #5373.

Bank of America first reported a position in PRLD in Q3 2020 and has held it in 23 quarters since. The position peaked at $1.11M in Q3 2022. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Bank of America held 56,525 shares of Prelude Therapeutics worth $193K as of Q1 2026.
  • Bank of America bought 46,717 Prelude Therapeutics shares in Q1 2026, an estimated $122K.
  • Prelude Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5373 holding.
  • Bank of America first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Bank of America's Prelude Therapeutics position peaked at $1.11M in Q3 2022.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.